Considerations on the sodium retention in nephrotic syndrome.
Renin-angiotensin-aldosterone system, plasma atrial natriuretic peptide (PANP), and blood volume (BV) have been investigated in 20 nephrotic patients with normal renal function and with (group 1; n = 12) or without (group 2; n = 8) sodium retention. Patients of group 1 had a plasma albumin (PALB) concentration < 1.7 g/dl, low BV and PANP levels, a reduced fractional excretion of lithium (FELi), and high plasma angiotensin II levels. Patients of group 2 had PALB > 1.7 g/dl, and the other parameters were normal. The spontaneous intake of dietary sodium was lower in group 1 than in group 2. In all patients the BV was directly correlated with PALB, and the plasma renin activity (PRA) was inversely correlated with both BV and PALB. A nonlinear inverse relationship was present between plasma aldosterone (PALD) levels and fractional excretion of sodium (FENa). The acute expansion of the BV in patients of group 1 normalized PRA, PALD, PAII, FENa, and FELi and increased PANP. The administration of spironolactone to the patients of both groups had variable effects on FENa, did not modify PRA and PALD, and reduced body weight, PANP, and FELi, thus suggesting that the reduction of BV induced by the drug increased the proximal reabsorption of sodium. Three additional patients who had sodium retention, PALB of 2.3-2.4 g/dl, normal PRA and PALD, elevated urinary excretion of aldosterone, and a slightly low PANP showed a spontaneous normalization of urinary aldosterone and PANP associated with natriuresis and weight loss, but thereafter urinary aldosterone increased, PANP decreased, and the sodium retention began again. Our data suggest that in nephrotic patients with severe hypoalbuminemia, contraction of BV plays a major role in promoting the sodium retention through the activation of compensatory hormonal mechanisms. On the other hand, when PALB is not severely reduced, the patients have normal BV, but they are very sensitive to small changes of BV which are better evidenced by modifications of the urinary excretion of aldosterone and PANP rather than by the profiles of PRA and PALD.
Usberti
M
M
Servizio di Nefrologia e Dialisi, Ospedale di Leno (BS), Italia.
Gazzotti
R M
RM
Poiesi
C
C
D'Avanzo
L
L
Ghielmi
S
S
D000293:Adolescent; D000328:Adult; D009320:Atrial Natriuretic Factor / Q000097:blood; D001810:Blood Volume / Q000502:physiology; D004232:Diuretics; D006801:Humans; D007668:Kidney / Q000378:metabolism* / Q000503:physiopathology; D008094:Lithium / Q000493:pharmacokinetics; D008875:Middle Aged; D009404:Nephrotic Syndrome / Q000188:drug therapy / Q000378:metabolism* / Q000503:physiopathology; D010446:Peptide Fragments / Q000097:blood; D012084:Renin-Angiotensin System / Q000502:physiology; D012709:Serum Albumin / Q000032:analysis; D012964:Sodium / Q000378:metabolism*; D012982:Sodium, Dietary / Q000008:administration & dosage; D013148:Spironolactone / Q000627:therapeutic use
D004232:Diuretics; D010446:Peptide Fragments; D012709:Serum Albumin; D012982:Sodium, Dietary; C074733:ANF (4-28), Leu(8,18)-Ile(12)-Ala(20)-MePhe(26)-Tyr(28)-Pro(29)-; D013148:Spironolactone; D009320:Atrial Natriuretic Factor; D008094:Lithium; D012964:Sodium